61081-34-3

Basic information

• Product Name: 1-[(methylsulfonyl)methyl]-4-nitrobenzene
• Synonyms: 1-[(methylsulfonyl)methyl]-4-nitrobenzene;1-(Methanesulfonylmethyl)-4-Nitrobenzene;1-(Methanesulfonylmethyl)-4-Nitrobenzene(WX682916)
• CAS NO: 61081-34-3
• Molecular Formula: C₈H₉NO₄S
• Molecular Weight: 215.22636
• Mol File: 61081-34-3.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 459.8°Cat760mmHg
• Flash Point: 231.9°C
• Appearance: /
• Density: 1.387g/cm³
• Vapor Pressure: 3.37E-08mmHg at 25°C
• Refractive Index: 1.569
• CAS DataBase Reference: 1-[(methylsulfonyl)methyl]-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(methylsulfonyl)methyl]-4-nitrobenzene(61081-34-3)
• EPA Substance Registry System: 1-[(methylsulfonyl)methyl]-4-nitrobenzene(61081-34-3)

Safety Data

• Hazardous Substances Data: 61081-34-3(Hazardous Substances Data)

Usage

General Description

1-[(methylsulfonyl)methyl]-4-nitrobenzene, also known as Dibenzosulfone, is a chemical compound with the molecular formula C8H9NO4S. It is a yellow crystalline solid that is used in the production of dyes, pigments, and pharmaceuticals. 1-[(methylsulfonyl)methyl]-4-nitrobenzene is also used as an intermediate in the synthesis of various organic compounds. It is considered to be moderately toxic and an irritant to the skin, eyes, and respiratory system, and should be handled with caution. Additionally,

InChI:InChI=1/C8H9NO4S/c1-14(12,13)6-7-2-4-8(5-3-7)9(10)11/h2-5H,6H2,1H3

Upstream product

• 20277-69-4 sodium methansulfinate 
• 100-14-1 4-nitrobenzyl chloride 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 51392-53-1 4-nitrobenzyl methyl sulfide 
• 100-39-0 benzyl bromide 
• 77-78-1 dimethyl sulfate 
• 3112-90-1 benzyl-methyl sulfone 
• 7697-37-2 nitric acid 
• 619-75-0 1-dibromomethyl-4-nitro-benzene 
• 2386-57-4 methanesulfonic acid sodium salt 
• 104-03-0 4-nitrobenzeneacetic acid 
• 619-73-8 4-nitrobenzyl chloride 
• 555-16-8 4-nitrobenzaldehdye 

Downstream Products

• 24176-70-3 4-[(methylsulfonyl)methyl]aniline 
• 5440-67-5 2-(4-nitrobenzyl)-2-nitropropane 
• 62-23-7 4-nitro-benzoic acid 
• 82720-39-6 Acridin-9-yl-(4-methanesulfonylmethyl-phenyl)-amine; hydrochloride 
• 635702-62-4 1-[1-methyl-1-(methylsulfonyl)ethyl]-4-nitrobenzene 
• 120383-85-9 1-(cyclopropylmethyl)-4-nitrobenzene 

Relevant articles and documents

NAMPT MODULATORS

Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

An efficient approach for the synthesis of novel methyl sulfones in acetic acid medium and evaluation of antimicrobial activity

A series of nine methyl sulphones (3a-3i) starting from the aldehydes (1a-1i) were synthesized in two consecutive steps. In the first step, preparation of allyl alcohols (2a-2i) from their corresponding aldehydes by the reaction of sodium borohydride in methanol at room temperature is reported. Finally, methyl sulphones are synthesized by condensing sodium methyl sulfinates with allyl alcohols in the presence of BF3.Et2O in acetic acid medium at room temperature for about 2-3 h. The reaction conditions are simple, yields are high (85%-95%), and the products were obtained with good purity. All the synthesized compounds were characterized by their 1H, 13C NMR, and mass spectral analysis. All the title compounds were screened for antimicrobial activity. Among the compounds tested, the compound 3f has inhibited both Gram positive and Gram negative bacteria effectively and compound 3i has shown potent antifungal activity. These promising components may help to develop more potent drugs in the near future for the treatment of bacterial and fungal infections.

Bromine structural domain inhibitor compound and application thereof

The invention relates to a bromine structural domain inhibitor and provides a compound shown in a general formula I, pharmaceutical salt, an enantiomer, a diastereoisomer, an atropisomer, racemate, apolymorphic substance and solvate of the compound or an isotope labelled compound (including a deuterium substituted compound), a preparation method of the compound, pharmaceutical composition containing the compound and an application of the above components in pharmaceuticals.